COST-EFFECTIVENESS ANALYSES FOR REFRACTORY OVERACTIVE BLADDER- A SYSTEMATIC LITERATURE REVIEW
Author(s)
Yehoshua A*1;Malone DC1;Gillard P2, Globe D2 1University of Arizona, Tucson, AZ, USA, 2Allergan, Inc., Irvine, CA, USA
Presentation Documents
OBJECTIVES: To assess the cost-effectiveness analyses for refractory overactive bladder (OAB). METHODS: A systematic literature review of economic evaluations of therapies for OAB was conducted using PubMed. For inclusion, studies had to compare two or more OAB treatments including at least one third-line treatment according to the American Urological Association. Articles were excluded if the study population was classified as neurogenic or predominantly stress incontinence. RESULTS: The initial search yielded 654 articles. After title review, 92 abstracts were identified as potentially eligible articles. Sixty-five abstracts were excluded because they did not meet inclusion criteria. Twenty-seven full-text articles were evaluated, of which 19 studies were excluded for lack of third-line treatment and two studies were excluded because OAB was classified as neurogenic. Of the six included studies, five were decision models, and one was a prospective cohort. Three of the decision models compared onabotulinumtoxin A to sacral nerve modulation with one of the models also allowing continued anticholinergic use as an additional intervention. One decision model compared onabotulinumtoxin A to anticholinergics. The remaining decision model compared peripheral tibial nerve stimulation to extended-release tolterodine. All of the studies were published recently, between 2009 and 2011. In four of the studies the perspective was “societal,” and in the remaining two it was from the perspectives of government payers. All decision analyses were based on direct medical costs and did not include the cost of lost productivity. Most of the studies based costs and utility scores on women with stress incontinence, not patients with refractory urge incontinence. No studies used direct comparative data or long-term evidence from clinical studies to evaluate refractory treatments. CONCLUSIONS: Few published economic evaluations exist that assess treatments for refractory OAB. Additional studies on the effectiveness of refractory OAB treatments are needed to accurately assess the cost-effectiveness of these interventions.
Conference/Value in Health Info
2013-05, ISPOR 2013, New Orleans, LA, USA
Value in Health, Vol. 16, No. 3 (May 2013)
Code
PUK11
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Urinary/Kidney Disorders